LEVOSIMENDAN KABI 2.5 mg/ml, concentrate for solution for infusion bottle, 5 ml
Active ingredients: Levosimendan
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Concentrate for solution for infusionbottle, 5 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LEVOSIMENDAN KABI 2,5 mg/mL, solution à diluer pour perfusion
- Pharmaceutical form
- solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon en verre de 5 mL
- Marketing authorisation holder
- FRESENIUS KABI FRANCE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Nov 2025
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67522379CIP75508658CIP133400955086581Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVOSIMENDANsolution | 2,5 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.